Experimental radiosensitizer therapy of malignant tumor transplanted to nude mice. (5). Radiosensitive effect of immidazole compounds for human maxillary carcinoma.:(5) Radiosensitive effect of inunidazole compounds for human maxillary carcinoma

スポンサーリンク

概要

論文の詳細を見る
The purpose of our investigation is to compare the radio-enhancement of three imidazole compounds to human oral malignant tumor transplanted on nude mice.<BR>Methods and evaluation: Battelle Columbus Laboratories Protocol.<BR>Tumor: PNC-1-JCK=human maxillary poorly differentiated squamous cell carcinoma.<BR>Subjects: Male CD-1 (ICR) nu/nu, BALBc nu/nu and conventional C 57 BL/6 N (age 10 weeks, 20-25g body weight).<BR>Imidazole compounds: Misonidazole (MISO) 20mg/mouse, dinitroimidazole ethanol (DNIE) 10mg/mouse and 5-methoxy carbonyl-2-methyl sulfinyl-l-methyl imidazole (KIH-3) 40mg/mouse.<BR>Tumors were transplanted to the subcutaneous region of the right thigh of CD-1 (ICR) nu/nu.<BR>Radiation: <SUP>60</SUP>Co 15 Gy local radiation.<BR>These imidazole compounds were administrated into the abdomen of the CD-1 (ICR) nu/nu prior to 30 minutes of local irradiation.<BR>NK activity was compared among CD-1 (ICR) nu/nu, BALBc nu/nu and conventional<BR>C 57 BL/6 N.<BR>Results: Radiosensitive effect was evaluated for MISO 20mg+<SUP>60</SUP>Co 15 Gy group. DNIE 10mg+<SUP>60</SUP>Co 15 Gy and KIH-3 40mg+<SUP>60</SUP>Co 15 Gy groups were observed to show radioprotective effects rather than radiosensitivity.<BR>% NK activity was as follows:<BR>CD-1 (ICR) nu/nu, 4.9 in YAC-1 100:1; 7.0 in RL-male 100:1. BALBc nu/nu 24.6 in YAC-1 100:1; 15.9 in RL-male 100:1. C 57 BL/6 N 21.4 in YAC-1 100:1; 24.0 in RL-male 100:1.
社団法人日本口腔外科学会の論文

著者

関連論文

もっと見る

スポンサーリンク